EGFR and lung cancer: Subgroup analysis showed that the HR was even better in stage I–II patients (P < 0.0001; HR, 0.1003; 95% CI, 0.0236–0.427; Supplementary Fig. S2A), and that the discriminatory ability was effective for both EGFR wild-type lung cancer and lung cancer harboring activating EGFR mutations (Supplementary Fig. S2B).